Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) SingleDose Vial. Glenmark’s Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS.
According to IQVIA sales data for the 12-month period ending April 2026, the ProvayBlue Injection, 50 mg/10 mL (5 mg/mL) market achieved annual sales of around $19.0 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries.
